Illumina's stockholders re-elected members to its board of directors to a three-year term, until the company's 2015 annual meeting of stockholders. Blaine Bowman, Karin Eastham, Jay Flatley, and William Rastetter were each re-elected to serve as directors.
Bowman has been a director since January 2007. He was formerly the chairman, president, and CEO, and is currently a director, of Dionex, a manufacturer of analytical instruments. He holds a BS in physics from Brigham Young University and an MBA from Stanford University.
Eastham has been a director since July 2004. She currently provides consulting and executive coaching to companies in the healthcare industry in addition to serving on the boards of directors for several life science companies. She holds a BS and an MBA from Indiana University and is a certified public accountant.
Flatley has been Illumina's CEO and president since 1999. Previously, he served as president and CEO of Molecular Dynamics, later acquired by Amersham Pharmacia Biotech and now a part of GE Healthcare. He holds a BA in economics from Claremont McKenna College, and a BS and MS in industrial engineering from Stanford University.
Rastetter has been a director since November 1998. He has served as CEO and executive chairman of the board of Receptos, a privately held drug discovery and development company, which he co-founded, since 2009. He holds a BS in chemistry from Massachusetts Institute of Technology and an MA and PhD in chemistry from Harvard University.
Martha Trela, Pacific Biosciences' former vice president of marketing, has left the company and currently works as an industry consultant. Previously, she was vice president of commercial marketing at Affymetrix and vice president of world wide marketing at Applied Biosystems (now part of Life Technologies). Trela holds an MBA from the University of California, Berkeley's Haas School of Business and a BS in biology from Stanford University.